A review of contemporary diabetic kidney disease (DKD) therapy found that randomized trials of SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 receptor agonists significantly slowed eGFR decline and reduced albuminuria, raising the possibility that some patients may reach remission with guideline-directed care. The review also emphasizes that remission in DKD remains an emerging concept, with no standardized definition and limited long-term outcomes data.

Why It Matters To Your Practice

• DKD has traditionally been managed as a progressive complication of diabetes mellitus (DM), but newer therapies are shifting expectations toward possible remission in selected patients.

• For NPs and PAs, this reframing may influence how you set treatment goals, monitor kidney markers, and counsel patients about prognosis.

• The review highlights that remission is generally framed as stable or physiologic eGFR decline with minimal or resolved albuminuria.

Clinical Benefits

• SGLT2 inhibitors, mineralocorticoid receptor antagonists, and GLP-1 receptor agonists have shown meaningful kidney and cardiovascular benefits in randomized trials.

• Observed benefits include slower loss of kidney function and lower albuminuria, both of which are clinically relevant targets in DKD management.

• These agents may help move care beyond simply delaying progression toward achieving better overall renal and cardiometabolic outcomes.

Managing Risks

• Do not assume remission is established or durable; the review notes a lack of standardized criteria and long-term follow-up data.

• Continue routine surveillance of eGFR, urine albumin, blood pressure, glycemic control, and medication tolerance even when markers improve.

• Use shared decision-making when discussing remission language so patients understand the promise of treatment without overestimating certainty.

The Bottom Line

• DKD remission is becoming a plausible treatment goal as newer pharmacologic therapies improve kidney and cardiovascular outcomes.

• In practice, the opportunity is real, but definitions and long-term evidence still need to catch up before remission can be used as a standardized endpoint.